A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Kalyan Nadiminti, Yogesh Jethava, Jillna Claus et al.|Blood|2018Cited by 5
Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)Kalyan Nadiminti, Yogesh Jethava, Christopher Strouse et al.|Transplantation and Cellular Therapy|2019Cited by 3
A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Christopher Strouse, Yogesh Jethava, Margarida Silverman et al.|Transplantation and Cellular Therapy|2019Cited by 1